NCM
FATE icon

Narwhal Capital Management’s Fate Therapeutics FATE Stock Holding History

Narwhal Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.3K Hold
12,700
– – ﹤0.01% 155
2026
Q1 		$15.2K Hold
12,700
– – ﹤0.01% 168
2025
Q4 		$12.5K Hold
12,700
– – ﹤0.01% 163
2025
Q3 		$16K Hold
12,700
– – ﹤0.01% 163
2025
Q2 		$14.2K Buy
+12,700
New +$14.8K ﹤0.01% 161

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Narwhal Capital Management's FATE Position: Q2 2026 in Review

Narwhal Capital Management held its Fate Therapeutics (FATE) position steady in Q2 2026 at 12,700 shares worth $34.3K. The position accounts for ﹤0.01% of the portfolio, ranked #155.

Narwhal Capital Management first reported a position in FATE in Q2 2025 and has held it in 5 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Narwhal Capital Management held 12,700 shares of Fate Therapeutics worth $34.3K as of Q2 2026.
  • Narwhal Capital Management left its Fate Therapeutics share count unchanged in Q2 2026.
  • Fate Therapeutics made up ﹤0.01% of Narwhal Capital Management's portfolio in Q2 2026, its #155 holding.
  • Narwhal Capital Management first reported a position in Fate Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Narwhal Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.